Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
NASDAQ:DNLI
Price:
20.77 USD
-2.53%
Market Closed
Updated:
Jun 9, 2024
Denali Therapeutics Inc
Total Current Liabilities
|
Denali Therapeutics Inc
Total Current Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Total Current Liabilities
$82.6m
|
CAGR 3-Years
15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Denali Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
82.6m
USD
82.6m
USD
Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Total Current Liabilities amounts to 82.6m USD.
What is Denali Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
14%
14%
Over the last year, the Total Current Liabilities growth was -79%. The average annual Total Current Liabilities growth rates for Denali Therapeutics Inc have been 15% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
